On this page
TRIP11
thyroid hormone receptor interactor 11
TRIP11 is located on the long (q) arm of chromosome 14, at band 14q32.12. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 14 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The TRIP11 gene encodes thyroid receptor-interacting protein 11 (TRIP-11), a large protein that helps maintain the structure and function of the Golgi apparatus across different cell types. The Golgi apparatus serves as a cellular processing centre where newly synthesised proteins undergo modification before being transported to their final destinations. Although TRIP-11 is present throughout the body, research suggests it has a particularly crucial role in chondrocytes, the specialised cells responsible for cartilage formation during skeletal development.
Variants in TRIP11 follow an autosomal recessive inheritance pattern, meaning that two altered copies of the gene must be present for a condition to develop. Pathogenic changes in this gene are associated with achondrogenesis type 1A, also known as the Houston-Harris type, a severe skeletal dysplasia characterised by profound bone development abnormalities. The condition results in extremely short limbs, a narrow chest with fragile ribs, and absent or severely reduced bone formation in the skull, spine, and pelvis.
What the gene does
TRIP-11 functions primarily as a structural and regulatory component within the Golgi apparatus, contributing to the maintenance of this organelle's distinctive architecture. The protein participates in tethering vesicles within the Golgi, facilitating the organised transport of cargo proteins through the secretory pathway. Research suggests that TRIP-11 coordinates the docking and fusion of transport vesicles, ensuring that proteins moving through the Golgi receive appropriate modifications.
The protein interacts with RAB2A, a small GTPase involved in regulating membrane trafficking between the endoplasmic reticulum and Golgi apparatus. Through these interactions, TRIP-11 helps coordinate the complex choreography of vesicle transport essential for cellular secretion. In chondrocytes, this function becomes particularly critical during the production and secretion of extracellular matrix components necessary for cartilage formation. The protein's role in maintaining Golgi structure appears especially important during the rapid growth and differentiation that occurs in developing skeletal tissue, where high levels of protein synthesis and secretion are required to build the cartilaginous framework that will later ossify into bone.
Video: Genetics 101
Chromosome location
TRIP11 is located on the long arm of chromosome 14 at position 14q32.12. This chromosomal region contains numerous genes involved in diverse cellular functions. The gene spans a substantial genomic region encoding a large protein product of 1,979 amino acids, reflecting the complex structural requirements for its role in Golgi organisation and vesicle tethering.
Protein structure
The TRIP-11 protein comprises 1,979 amino acids organised into several distinct structural features. An amphipathic lipid-packing sensor domain spanning amino acids 2-38 at the N-terminus is required for tethering of intra-Golgi vesicles, enabling the protein to interact with membrane surfaces. The majority of the protein, from amino acids 52-1773, forms an extensive coiled coil structure that likely mediates protein-protein interactions and provides a scaffold for Golgi organisation.
Two regions involved in RAB2A binding are present at amino acids 1017-1195 and 1325-1599, allowing the protein to interact with this key regulator of membrane trafficking. Near the C-terminus, a GRIP domain occupies amino acids 1774-1823, a structural motif typically involved in Golgi targeting and retention. A disordered region extends from amino acids 1873-1920, which may provide flexibility for protein interactions or regulatory modifications. This domain architecture enables TRIP-11 to function as both a structural component and a regulatory hub within the Golgi apparatus.
Key variants
Pathogenic variants in TRIP11 typically disrupt the protein's ability to maintain Golgi structure or coordinate vesicle trafficking, with particularly severe consequences for rapidly developing skeletal tissue. Several variants have been identified that cause achondrogenesis type 1A, generally leading to loss of protein function through premature termination, altered protein folding, or disrupted domain function. The severity of skeletal abnormalities reflects the critical importance of functional TRIP-11 during cartilage development and bone formation in early embryonic and foetal stages.
No pathogenic or likely-pathogenic ClinVar variants recorded yet for this gene.
Associated conditions
Variants in TRIP11 cause achondrogenesis type 1A (also designated the Houston-Harris type), a severe skeletal dysplasia characterised by profound abnormalities in bone and cartilage development. Affected individuals typically present with extremely short limbs, a narrow chest, ribs that fracture easily, and absent or severely deficient ossification in the skull, spine, and pelvis. The condition generally results in perinatal lethality due to respiratory insufficiency related to the underdeveloped chest cavity and rib abnormalities. The skeletal features reflect the essential role of TRIP-11 in chondrocyte function during the formation of the cartilaginous skeleton that serves as the template for subsequent bone development.
No disease links recorded for this gene in our reference set.
Inheritance pattern
Conditions caused by pathogenic TRIP11 variants typically follow autosomal recessive inheritance.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
UK clinical status
TRIP11 appears on several NHS Genomic Medicine Service PanelApp panels with green classification, indicating strong evidence supporting its role in skeletal development disorders. The gene is included in the DDG2P panel, the Fetal Anomalies panel (version R21), and the Skeletal Dysplasia panel (version R104). These classifications reflect clinical consensus that TRIP11 variants represent an established cause of severe skeletal abnormalities detectable during prenatal imaging or at birth, supporting its inclusion in genetic testing pathways for suspected skeletal dysplasias within the NHS.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What inheritance pattern does TRIP11 follow?
TRIP11-related conditions follow an autosomal recessive pattern, meaning an individual must inherit two altered copies of the gene (one from each parent) for the condition to develop. Carriers with one variant copy typically show no symptoms.
Why does TRIP11 particularly affect skeletal development?
Although TRIP-11 functions in the Golgi apparatus across many cell types, chondrocytes in developing cartilage require particularly high levels of protein secretion to produce extracellular matrix components. Disruption of Golgi function in these cells severely impairs the formation of the cartilaginous skeleton during early development.
Can TRIP11 variants be detected through carrier screening?
Yes, TRIP11 is included on autosomal recessive carrier screening panels. Individuals with family history of skeletal dysplasia or consanguinity may wish to discuss carrier screening with a healthcare provider or genetic counsellor to understand their reproductive risks.